Skip to main content
Journal cover image

A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.

Publication ,  Journal Article
Olsen, EA; Cram, DL; Ellis, CN; Hickman, JG; Jacobson, C; Jenkins, EE; Lasser, AE; Lebwohl, M; Leibsohn, E; Medansky, RS
Published in: J Am Acad Dermatol
March 1991

The efficacy and safety of clobetasol propionate 0.05% scalp application was evaluated in 378 patients with moderate to severe scalp psoriasis in a double-blind vehicle-controlled parallel group study. After 2 weeks of twice-daily applications, 81% receiving active drug versus 22% receiving vehicle had clearing of 50% or greater. Complete clearing was seen in 26% with active drug and 1% with vehicle. Local side effects were primarily burning or stinging in 11% and 10% of patients treated on an active or a vehicle regimen, respectively. The morning cortisol levels of 168 patients were checked at baseline and again after 2 weeks of drug therapy. Subnormal morning plasma cortisol values were seen in 5% of the patients receiving active drug and in 5% receiving vehicle; 13% of those taking active drug versus 5% taking vehicle had a 50% or greater decrease in morning cortisol at the 2-week visit compared with baseline values. Clobetasol propionate 0.05% scalp application appears to be a safe and an effective treatment for scalp psoriasis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Acad Dermatol

DOI

ISSN

0190-9622

Publication Date

March 1991

Volume

24

Issue

3

Start / End Page

443 / 447

Location

United States

Related Subject Headings

  • United States
  • Scalp Dermatoses
  • Psoriasis
  • Middle Aged
  • Male
  • Hydrocortisone
  • Humans
  • Female
  • Double-Blind Method
  • Dermatology & Venereal Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Olsen, E. A., Cram, D. L., Ellis, C. N., Hickman, J. G., Jacobson, C., Jenkins, E. E., … Medansky, R. S. (1991). A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol, 24(3), 443–447. https://doi.org/10.1016/0190-9622(91)70069-e
Olsen, E. A., D. L. Cram, C. N. Ellis, J. G. Hickman, C. Jacobson, E. E. Jenkins, A. E. Lasser, M. Lebwohl, E. Leibsohn, and R. S. Medansky. “A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.J Am Acad Dermatol 24, no. 3 (March 1991): 443–47. https://doi.org/10.1016/0190-9622(91)70069-e.
Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991 Mar;24(3):443–7.
Olsen, E. A., et al. “A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.J Am Acad Dermatol, vol. 24, no. 3, Mar. 1991, pp. 443–47. Pubmed, doi:10.1016/0190-9622(91)70069-e.
Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, Lasser AE, Lebwohl M, Leibsohn E, Medansky RS. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991 Mar;24(3):443–447.
Journal cover image

Published In

J Am Acad Dermatol

DOI

ISSN

0190-9622

Publication Date

March 1991

Volume

24

Issue

3

Start / End Page

443 / 447

Location

United States

Related Subject Headings

  • United States
  • Scalp Dermatoses
  • Psoriasis
  • Middle Aged
  • Male
  • Hydrocortisone
  • Humans
  • Female
  • Double-Blind Method
  • Dermatology & Venereal Diseases